

SILICONE RUBBER
USP<88> class VI Study
Test Report

Client**WYNCA TINYO SILICONE
CO., LTD**

Testing Institution**Biocompatibility Lab. of Leon
Biotech. Co. Ltd.**

Report No.**R-USP88-KL20160501**

- Note:**
1. The content of this test plan is invalid if it is not presented as the entire test plan.
 2. Any unauthorized alteration, forgery or falsification of the content or appearance of this test plan is unlawful and offenders may be prosecuted to the fullest extent of the law.
 3. The results shown in this test plan refer to the test article(s) tested only.



Contents

| | |
|-----------------------------------|----|
| Schedule | 2 |
| Study Director | 2 |
| Study Personnel..... | 2 |
| Test Institution..... | 3 |
| Client | 3 |
| Test Article Information..... | 4 |
| Statement of GLP Compliance..... | 5 |
| Quality Assurance Statement | 6 |
| Archiving..... | 7 |
| Objective | 8 |
| Test System | 9 |
| Material and Method | 12 |
| Results | 17 |
| Conclusion..... | 22 |
| Table..... | 23 |
| Test Plan Amendment | 24 |
| Reference..... | 25 |

Schedule

| | |
|------------------------------|---|
| Study | USP<88> class VI Study |
| Test article | SILICONE RUBBER |
| Service No. | KL20160501 |
| Study Initiation date | 2016.05.24 |
| Experimental starting date | 2016.05.27 |
| Experimental completion date | 2016.06.29 |
| Study completion date | See Study Director's signature date in the report |

Study Director

| | |
|---------|--|
| Name | Yu Jung Pan |
| Address | 4F.-2, No.288-8, Xinya Rd., Qianzhen Dist., Kaohsiung City 806, Taiwan |

Study Personnel

| | |
|--------------|---------------------------------------|
| Participants | Yu Jung Pan, Hsuan-Wen Wu, Ai Jie Han |
|--------------|---------------------------------------|

Test Institution

| | |
|---------|--|
| Name | Biocompatibility Lab. of LEON Biotech. Co., Ltd. |
| Address | 4F.-2, No.288-8, Xinya Rd., Qianzhen Dist., Kaohsiung City 806, Taiwan |
| Contact | Ming-Yang Tsao (07) 841-9003 ming_yang@seed.net.tw |

Client

| | |
|---------|---|
| Name | WYNCA TINYO SILICONE CO., LTD |
| Address | No.36, Jingling Road, Qingyuan High-tech Zone, Qingyuan , Guangdong , China. |
| Contact | Phone: 0763-3608635 FAX: 0763-3608669 |

Test Article Information

| | |
|--|---|
| Name | SILICONE RUBBER |
| Manufacture Date | 2016.04.12 |
| Expiry Date | N/A |
| Lot No. | N/A |
| Model | TYE771 |
| Storage Condition | Room Temperature |
| Sterilization Condition | EO |
| Package | Plastic bag |
| Physical Description | Polysiloxane, Silica, Siloxane Oligomer |
| Appearance Description | Colorless-transparent, sheet |
| Category | Medical Device |
| Pre-treatment | N/A |
| ✦ Sponsor, who provided test facility with the test article information, will take full responsibility for all the facts of it. | |
| Received date | 2016.05.03 |
| Test article no. | KL20160501-a |



Statement of GLP Compliance

Study activities performed by Biocompatibility Lab. of LEON Biotech. Co., Ltd. are carried out in compliance with current OECD Principles of Good Laboratory Practice (Organization for Economic Cooperation and Development, Paris, ENV/MC/CHEM (98) 17) and U.S. Food and Drug Administration Good Laboratory Practice Regulations, 21 CFR Part 58. The study was conducted in accordance with the test plan and standard operating procedures and monitored in conformity with the test plan. All laboratory data are accurately recorded and verified. Biocompatibility Lab. of LEON Biotech. Co., Ltd. makes no GLP compliance claim for characterization and verification (6.2.2 and 6.2.3 in OECD principle on Good Laboratory Practice) of the test article identity and properties, which are the responsibility of the sponsor.

**Study
Director**

Yu Jung Pan

Yu Jung Pan / LEON Biotech. Co. Ltd

2016.07.26

Date Completed

**Facility
Manager**

M. Y. Tsao

Ming-Yang Tsao / LEON Biotech. Co. Ltd

2016.07.26

Date Completed



Quality Assurance Statement

SILICONE RUBBER
USP<88> class VI Study

This study was inspected by Quality Assurance unit of LEON Biotech. Co. Ltd. Inspection activities included review of draft test plan, audit test procedure, and review of raw data and draft test report.

Study-base audit

| Study Phase | Inspection Date | Submitted date to Study Director and Facility Manager |
|---|-----------------|---|
| Test plan draft | 2016/05/25 | 2016/05/25 |
| Test Article extraction— Intracutaneous Test | 2016/05/27 | 2016/05/27 |
| Dose Administration— Systemic Injection Test | 2016/06/20 | 2016/06/20 |
| Dose Administration— Implant Test | 2016/06/21 | 2016/06/21 |
| Review of raw data | 2016/07/26 | 2016/07/26 |
| Test report draft | 2016/07/26 | 2016/07/26 |

The final report has been found to reflect the raw data obtained.

**Quality
Assurance
Manager**

Wei Ti Wang
Wei Ti Wang/ LEON Biotech. Co. Ltd

2016.07.26
Date Completed

Archiving

All the study-related raw data, records, protocol and the final report will be kept in GLP cabinet of archives room of Leon Biotech. for 5 years. All of the records and test articles are handled according to GLP guideline.

| Archiving List | |
|---------------------|--|
| Test Plan | Test plan Test plan amendment (if necessary) |
| Final Report | Final report copy Final report amendment (if necessary) |
| Raw Data | All test data sheet |
| Records | Application form Test article information Test article control form and other supplementary record |



Objective

The purpose of the study is to determine the biological response of animals to direct and indirect contact with the test article or injection of the test article extract. This study was conducted following USP<88>.

Test System

1. For Systemic Injection Test

| | |
|---|--|
| Species/ Strain | ICR Mice |
| Resource | LASCO Co. Ltd. (base on SOP-Q02) |
| Reason | According to USP<88> |
| Body weights | 17~23 g |
| Sex | Female, female should be nulliparous and not pregnant. |
| Numbers | 40 |
| Quarantine/ acclimation | Once animals are introduced in-house, they are subjected to quarantine and acclimatize before treatment. Animals are selected based on health status by qualified staff. (according to SOP-A02) |
| Animal restraint | The restraint of animals is according to internal document of standard operating procedure SOP-T00. |
| Identification | |
| Individual identification | Animals are identified by tail-marking. |
| Cage identification | Cages are properly labeled for identification including species/strain, sex, in-housing date, IACUC number, animal I.D. number. |
| Housing condition (according to SOP-A01) | |
| Environment temperature | 22±3°C |
| Humidity | 30~70% |
| Cage and animal number | 5 animals/cage |
| Fodder/ Supply | Lab Diet; <i>ad libitum</i> |
| Drinking water/ Supply | Tap water; <i>ad libitum</i> |

2. For Intracutaneous Injection Test

| | |
|---|---|
| Species/ Strain | New Zealand White Rabbit (NZW) |
| Resource | Livestock Research Institute, Council of Agriculture, Executive Yuan (TLRI) (base on SOP-Q02) |
| Reason | According to USP<88> |
| Body weights | >2 kg |
| Sex | Female, female should be nulliparous and not pregnant. |
| Numbers | 4 |
| Quarantine/ acclimation | Once animals are introduced in-house, they are subjected to quarantine and acclimatize before treatment. Animals are selected based on health status by qualified staff. (according to SOP-A02) |
| Animal restraint | The restraint of animals is according to internal document of standard operating procedure SOP-T00. |
| Identification | |
| Individual identification | Animals are identified by ear-marking. |
| Cage identification | Cages are properly labeled for identification including species/ strain, sex, in-housing date, IACUC number, animal I.D. number. |
| Housing condition (according to SOP-A01) | |
| Environment temperature | 23±3°C |
| Humidity | 30~70% |
| Cage and animal number | 1 animals/cage |
| Fodder/ Supply | Lab Diet; <i>ad libitum</i> |
| Drinking water/ Supply | Tap water; <i>ad libitum</i> |

3. For Implant Test

| | |
|--|---|
| Species/Strain | Rat/SD |
| Resource | LASCO Co. Ltd. (base on SOP-Q02) |
| Reason | According to USP<88> |
| Body weights | 225~350 g |
| Sex | Female, female should be nulliparous and not pregnant. |
| Numbers | 5 |
| Quarantine/ acclimation | Once animals are introduced in-house, they are subjected to quarantine and acclimatize before treatment. Animals are selected based on health status by qualified staff. (according to SOP-A02) |
| Animal restraint | The restraint of animals is according to internal document of standard operating procedure SOP-T00. |
| Identification | |
| Individual identification | Animals are identified by tail-marking and ear-marking |
| Cage identification | Cages are properly labeled for identification including species/strain, sex, in-housing date, IACUC number, animal I.D. number. |
| Housing condition (according to SOP-A01) | |
| Environment temperature | 22±3°C |
| Humidity | 30~70% |
| Cage and animal number | 2~5 animals/cage |
| Fodder/ Supply | Lab Diet; <i>ad libitum</i> |
| Drinking water/ Supply | Tap water; <i>ad libitum</i> |

Material and Method

Reagent

1. 0.9% normal saline (Tai Yu Pharmaceutical Co., Ltd. Lot. No.QL3003)
2. Cottonseed oil (Sigma, C7767. Lot. No.MKBS9702V)
3. 100% EtOH (Ferak Berlin GmbH, Lot. No.574105)
4. PEG 400 (Fluka, 81172 Lot. No.BCBH2687V)
5. USP High Density Polyethylene RS (Lot. No.I0K217)

Preparation

Systemic and Intracutaneous Testing Preparation:

Prior to extraction, the test articles were washed two times with 70ml of distilled water. The test article samples prepared for extraction with cottonseed oil were dried at 50°C for 1±0.1 hours.

The test article was combined with vehicle at a ratio of 3cm² per 1 mL per USP guidelines (Thickness: 0.5~1mm). The test article was separately extracted in 0.9% Saline (NaCl), Cottonseed oil (CSO), 1:20 EtOH/0.9% saline, and PEG 400 at 50 °C for 72±2 hours. Properly prepared test articles were placed in separate extraction bottles, and to each bottle the appropriate medium was added. The extraction medium completely covered the test article. Each extracting medium (control article) was prepared for parallel treatments and comparisons. Each control article was prepared in the same manner as the test article. After extraction, cool to about room temperature for test. Do not use extract for test after 24 hours.

Subcutaneous Implant Testing Preparation:

The test articles and control articles (USP High Density Polyethylene RS) were cut into approximately 1 mm × 10 mm. The control article was sterilized by dipping in 75% ethanol prior to implantation.



Grouping

| Tests | Systemic injection | | | | | | | | Intracutaneous Injection | | | | Subcutaneous Implantation |
|--|--------------------|---|-----|---|----------------|---|---------|---|--------------------------|-----|----------------|---------|---------------------------|
| Test system | Mice | | | | | | | | Rabbits | | | | Rats |
| Extractant | NaCl | | CSO | | 1:20 EtOH/NaCl | | PEG 400 | | NaCl | CSO | 1:20 EtOH/NaCl | PEG 400 | |
| Group | T | C | T | C | T | C | T | C | T + C | | T + C | | 2T + 2C |
| Animal numbers | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 2 | | 2 | | 5 |
| ♦ T— Test group; C— Control group; T+C—Test and control group will be conducted in different area in one animal. | | | | | | | | | | | | | |

The tests were conducted with different animal as recommended by the classification of plastic of USP guidelines for Class VI (see Table 1). The species and number of animals used in this study are recommended by the USP<88> guidelines.

Dose Administration

1 Systemic Injection Test

- 1.1 Groups of 5 animals were injected with either the test article extract or the corresponding control article extract in the same amounts and by the same routes set forth below:

| Extract | Route | Dose/kg |
|---------|-----------------|---------|
| NaCl | Intravenous | 50 mL |
| CSO | Intraperitoneal | 50 mL |
| EtOH | Intravenous | 50 mL |
| PEG | Intraperitoneal | 10 g |

2 Intracutaneous Injection Test

- 2.1 A volume of 0.2 mL of each test article extract was injected intracutaneously at five sites on one side of each of two rabbits.
- 2.2 Two test article extract was used per rabbit. At five sites on the other side of each rabbit, 0.2 mL of the corresponding control article was injected.

3 Subcutaneous Implant Test

- 3.1 2 samples of the test article (Approximately 1 mm × 10 mm) were implanted into the subcutaneous on one side of the spine of each of 5 rats. In a similar fashion, 2 USP High Density Polyethylene RS (Approximately 1 mm × 10 mm) were implanted in the

subcutaneous of each animal.

Procedure

1 Systemic Injection Test:

1.1 Administration

1.1.1 Acclimated animals were weighed prior to dosing.

1.1.2 For the Systemic Injection Test, the PEG test article extract and the corresponding control were diluted with NaCl to obtain PEG concentration of approximately 200 mg/mL (with 4.1 volumes of NaCl).

1.1.3 The animals were observed for clinical signs immediately after injection, 4 hours after injection, and at 24, 48, and 72±2 hours after injection. Observations conducted included all clinical and toxicological signs. The animals were weighed at the end of the observation period.

1.2 Evaluation

1.2.1 If during the observation period, none of the animals treated with the extract of the test article shows a significantly greater biological reactivity than the animals treated with the control article, the test article meets the requirements of this test.

1.2.2 The test was considered negative if none of the animals injected with the test article show a significantly greater biological reaction than the animals treated with the control article. If two or more mice die, or show signs of toxicity such as convulsions or prostration, or if three or more mice lose more than 2 g of body weight, the test article does not meet the requirements of the test.


2 Intracutaneous Injection Test

2.1 Administration

2.1.1 On the day of the test, animals were weighed and clipped free of fur on the dorsal side.

2.1.2 For the Intracutaneous Test, the PEG test article extract and the corresponding control were diluted with NaCl to obtain PEG concentration of approximately 120 mg/mL (with 7.4 volumes of NaCl).

2.1.3 Two kinds of extract and its corresponding control solution will be injected in one rabbit (see figure upper right) and each kinds of extract will be conducted on



two rabbits.

2.1.4 The injection sites on each animal were observed for signs at 24, 48, and 72±2 hours after injection of the test article. Observations were scored according to the Table 2.

2.2 Evaluation

2.2.1 All average erythema and edema scores for the test and control sites at 24, 48 and 72 hours were totaled separately and divided by 12 (2 animals × 3 scoring periods × 2 scoring categories) to determine the overall mean score for the test article versus the corresponding control article. The requirements of the test were met if the difference between the test article and the control mean score was 1.0 or less.

2.2.2 The requirements of the test were met if the difference between the test article and control article mean reaction scores (erythema/edema) was 1.0 or less.

3 Implant Test

3.1 Administration

3.1.1 On the day of the test, the animals were weighed and the skin on both sides of the spinal column was clipped free of fur. Clean the clipped area with 75% EtOH while animal was anesthetized.

3.1.2 Using aseptic technique, make 2 midline incision (approximately 1.0 cm long) through the skin at the cranial and caudal regions on the dorsal surface.

3.1.3 Using blunt dissection, separate the fascia connecting skin to muscle to form a pocket (base of pocket approximately 2.0 cm from the line of implant).

3.1.4 Insert a sterile sample into each pocket, and close the incision with wound clips or sutures.

3.1.5 Implant 2 test samples and 2 control samples in each rats and the implantation will be conducted with five rats.

3.1.6 The animals were maintained for a period of at least 7 days.

3.1.7 At the end of the observation period, the animals were weighed and sacrificed by CO₂.

3.2 Evaluation

3.2.1 Cut the skin (dorsal surface) longitudinally and lay back. Carefully examine macroscopically the area of the tissue surrounding the implant.

3.2.2 Observe the test article and control implant sites for hemorrhage, necrosis,

discolorations, and infections, and record the observations. Measure encapsulation, if present, by recording the width of the capsule (from the periphery of the space occupied by the implant control or test article to the periphery of the capsule) rounded to the nearest 0.1 mm. Score encapsulation according to table below.

3.2.3 Calculate the differences between average scores for the test article and control sites. The requirements of the test were met if the difference does not exceed 1.0.

| Capsule Width | Score |
|----------------------|--------------|
| None | 0 |
| Up to 0.5 mm | 1 |
| 0.6 to 1.0 mm | 2 |
| 1.1 to 2.0 mm | 3 |
| Greater than 2.0 mm | 4 |

Results

Systemic Injection Test

The results showed that there were no significant clinical signs and obvious weight loss in either the control or test group (Table below).

The test was considered negative because no animal was dead or abnormally in all test groups.

| Group | Dose (ml/kg) | Sex | Animal No. | Body weight (g) | | *Sign of Toxicity |
|--|--------------|--------|-------------|-----------------|-------|-------------------|
| | | | | 0hr | 72hr | |
| Test (Test article NaCl extract) | 50 | female | M-160616-21 | 22.71 | 24.17 | None |
| | | | M-160616-22 | 21.21 | 22.10 | None |
| | | | M-160616-23 | 22.91 | 23.52 | None |
| | | | M-160616-24 | 22.23 | 23.20 | None |
| | | | M-160616-25 | 22.53 | 23.97 | None |
| Control (NaCl) | 50 | female | M-160616-36 | 20.65 | 19.44 | None |
| | | | M-160616-37 | 22.56 | 19.69 | None |
| | | | M-160616-38 | 20.90 | 19.70 | None |
| | | | M-160616-39 | 22.87 | 21.98 | None |
| | | | M-160616-40 | 22.98 | 23.76 | None |

| Group | Dose (ml/kg) | Sex | Animal No. | Body weight (g) | | *Sign of Toxicity |
|---------------------------------------|--------------|--------|-------------|-----------------|-------|-------------------|
| | | | | 0hr | 72hr | |
| Test (Test article CSO extract) | 50 | female | M-160616-16 | 22.06 | 24.41 | None |
| | | | M-160616-17 | 22.66 | 23.33 | None |
| | | | M-160616-18 | 22.01 | 23.94 | None |
| | | | M-160616-19 | 22.74 | 26.60 | None |
| | | | M-160616-20 | 22.80 | 23.21 | None |
| Control (CSO) | 50 | female | M-160616-06 | 22.59 | 22.94 | None |
| | | | M-160616-07 | 21.76 | 24.59 | None |
| | | | M-160616-08 | 22.42 | 24.56 | None |
| | | | M-160616-09 | 22.80 | 25.53 | None |
| | | | M-160616-10 | 20.00 | 19.94 | None |

| Group | Dose (ml/kg) | Sex | Animal No. | Body weight (g) | | *Sign of Toxicity |
|---|--------------|--------|-------------|-----------------|-------|-------------------|
| | | | | 0hr | 72hr | |
| Test (Test article EtOH extract) | 50 | female | M-160616-26 | 21.56 | 24.74 | None |
| | | | M-160616-27 | 20.54 | 22.79 | None |
| | | | M-160616-28 | 21.34 | 24.50 | None |
| | | | M-160616-29 | 22.81 | 24.53 | None |
| | | | M-160616-30 | 21.24 | 24.34 | None |
| Control (EtOH) | 50 | female | M-160616-31 | 21.35 | 24.48 | None |
| | | | M-160616-32 | 22.83 | 26.08 | None |
| | | | M-160616-33 | 22.69 | 24.14 | None |
| | | | M-160616-34 | 22.67 | 26.49 | None |
| | | | M-160616-35 | 22.80 | 24.66 | None |

| Group | Dose (g/kg) | Sex | Animal No. | Body weight (g) | | *Sign of Toxicity |
|---------------------------------------|-------------|--------|-------------|-----------------|-------|-------------------|
| | | | | 0hr | 72hr | |
| Test (Test article PEG extract) | 10 | female | M-160616-01 | 22.36 | 22.84 | None |
| | | | M-160616-02 | 22.14 | 25.21 | None |
| | | | M-160616-03 | 21.41 | 21.54 | None |
| | | | M-160616-04 | 21.83 | 23.06 | None |
| | | | M-160616-05 | 22.05 | 22.60 | None |
| Control (PEG) | 10 | female | M-160616-11 | 22.98 | 24.07 | None |
| | | | M-160616-12 | 22.16 | 22.29 | None |
| | | | M-160616-13 | 21.77 | 22.13 | None |
| | | | M-160616-14 | 22.26 | 24.15 | None |
| | | | M-160616-15 | 21.84 | 22.23 | None |

*: Summary of clinical observations - Immediately, 4, 24, 48, and 72 h after injection.

Intracutaneous Injection Test

The results showed that there were no significant clinical signs and gross findings in either the control or test group, and there were no mortalities. Erythema and oedema were only recorded in cottonseed oil (CSO) group. The difference between the test article and control article mean reaction scores (erythema/edema) was less than 1.0 (NaCl group: 0/12-0/12=0; CSO group: 39/12-32/12=0.58; EtOH group: 0/12-0/12=0; PEG group: 5/12-3/12=0.17). The test article meets

the requirements of the Intracutaneous Test (Table below, five injection site grades).

| Treated article | Sex | Animal No. | Items for Grading | Clinical Observation (time point/h) | | |
|------------------------------|-----|--------------|--------------------|-------------------------------------|----|----|
| | | | | 24 | 48 | 72 |
| Treatment group NaCl extract | F | RB-160303-01 | Erythema formation | 0 | 0 | 0 |
| | | | Edema formation | 0 | 0 | 0 |
| | F | RB-160303-04 | Erythema formation | 0 | 0 | 0 |
| | | | Edema formation | 0 | 0 | 0 |
| Control group "NaCl" | F | RB-160303-01 | Erythema formation | 0 | 0 | 0 |
| | | | Edema formation | 0 | 0 | 0 |
| | F | RB-160303-04 | Erythema formation | 0 | 0 | 0 |
| | | | Edema formation | 0 | 0 | 0 |

| Treated article | Sex | Animal No. | Items for Grading | Clinical Observation (time point/h) | | |
|-----------------------------|-----|--------------|--------------------|-------------------------------------|----|----|
| | | | | 24 | 48 | 72 |
| Treatment group CSO extract | F | RB-160303-01 | Erythema formation | 5 | 2 | 2 |
| | | | Edema formation | 5 | 0 | 0 |
| | F | RB-160303-04 | Erythema formation | 5 | 5 | 5 |
| | | | Edema formation | 5 | 5 | 0 |
| Control group "CSO" | F | RB-160303-01 | Erythema formation | 5 | 3 | 2 |
| | | | Edema formation | 3 | 0 | 0 |
| | F | RB-160303-04 | Erythema formation | 5 | 5 | 5 |
| | | | Edema formation | 3 | 1 | 0 |

| Treated article | Sex | Animal No. | Items for Grading | Clinical Observation (time point/h) | | |
|------------------------------|-----|--------------|--------------------|-------------------------------------|----|----|
| | | | | 24 | 48 | 72 |
| Treatment group EtOH extract | F | RB-160114-05 | Erythema formation | 0 | 0 | 0 |
| | | | Edema formation | 0 | 0 | 0 |
| | F | RB-160114-06 | Erythema formation | 0 | 0 | 0 |
| | | | Edema formation | 0 | 0 | 0 |
| Control group "EtOH" | F | RB-160114-05 | Erythema formation | 0 | 0 | 0 |
| | | | Edema formation | 0 | 0 | 0 |
| | F | RB-160114-06 | Erythema formation | 0 | 0 | 0 |
| | | | Edema formation | 0 | 0 | 0 |

| Treated article | Sex | Animal No. | Items for Grading | Clinical Observation (time point/h) | | |
|-----------------------------|-----|--------------|--------------------|-------------------------------------|----|----|
| | | | | 24 | 48 | 72 |
| Treatment group PEG extract | F | RB-160114-05 | Erythema formation | 3 | 0 | 0 |
| | | | Edema formation | 0 | 0 | 0 |
| | F | RB-160114-06 | Erythema formation | 2 | 0 | 0 |
| | | | Edema formation | 0 | 0 | 0 |
| Control group "PEG" | F | RB-160114-05 | Erythema formation | 0 | 0 | 0 |
| | | | Edema formation | 0 | 0 | 0 |
| | F | RB-160114-06 | Erythema formation | 3 | 0 | 0 |
| | | | Edema formation | 0 | 0 | 0 |

F: Female



Implantation Test

There were no overt signs of toxicity noted in either animal. Macroscopic evaluation of the test and control article implant sites showed no significant infection, encapsulation, necrosis, or discoloration. The test was considered negative, since in each rat the difference between the average scores for encapsulation for the test article and control article implant sites did not exceed 1.0 (0-0=0). The test article meets the requirements of the Implantation Test (Table below).

| Animal No. | R-160616-21 | | R-160616-22 | | R-160616-23 | | R-160616-24 | | R-160616-25 | |
|---------------|-------------|----|-------------|----|-------------|----|-------------|----|-------------|-----|
| Implant No. | T1 | T2 | T3 | T4 | T5 | T6 | T7 | T8 | T9 | T10 |
| Infection | - | - | - | - | - | - | - | - | - | - |
| Hemorrhage | - | - | - | - | - | - | - | - | - | - |
| Necrosis | - | - | - | - | - | - | - | - | - | - |
| Discoloration | - | - | - | - | - | - | - | - | - | - |
| Encapsulation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mean Score | 0 | | | | | | | | | |

-: No symptom

| Animal No. | R-160616-21 | | R-160616-22 | | R-160616-23 | | R-160616-24 | | R-160616-25 | |
|---------------|-------------|----|-------------|----|-------------|----|-------------|----|-------------|-----|
| Implant No. | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | C9 | C10 |
| Infection | - | - | - | - | - | - | - | - | - | - |
| Hemorrhage | - | - | - | - | - | - | - | - | - | - |
| Necrosis | - | - | - | - | - | - | - | - | - | - |
| Discoloration | - | - | - | - | - | - | - | - | - | - |
| Encapsulation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mean Score | 0 | | | | | | | | | |

-: No symptom

Conclusion

The 0.9% Sodium Chloride for Injection (NaCl), Cottonseed Oil (CSO), 1 in 20 Ethanol in NaCl (EtOH), and Polyethylene Glycol 400 (PEG) extracts of the test article “SILICONE RUBBER”, did not produce a significant biological response following subcutaneous implantation in rats, intracutaneous injection test in rabbits and systemic injection in mice. Therefore, the test article meets the requirements of the USP guidelines, for Class VI Plastics.

Table

1. Classification of Plastics

| Plastic Classes ^a | | | | | | Tests to be Conducted | | | |
|------------------------------|----|-----|----|---|----|--|----------------------|-----------------------------------|-------------------------|
| I | II | III | IV | V | VI | Test material | Animal | Dose | Procedures ^b |
| X | X | X | X | X | X | Extract of Sample in Sodium Chloride Injection | Mouse | 50mL/kg | A (IV) |
| X | X | X | X | X | X | | Rabbit or Guinea Pig | 0.2mL/animal at each 10 or 6sites | B (IC) |
| | X | X | X | X | X | Extract of Sample in 1 in20 Solution of Alcohol in Sodium Chloride Injection | Mouse | 50mL/kg | A (IP) |
| | X | X | X | X | X | | Rabbit or Guinea Pig | 0.2mL/animal at each 10 or 6sites | B (IC) |
| | | X | | X | X | Extract of Sample in Polyethelene Glycol 400 | Mouse | 10g/kg | A (IP) |
| | | | | X | X | | Rabbit or Guinea Pig | 0.2mL/animal at each 10 or 6sites | B (IC) |
| | | X | X | X | X | Extract of Sample in Vegetable Oil | Mouse | 50mL/kg | A (IP) |
| | | | X | X | X | | Rabbit or Guinea Pig | 0.2mL/animal at each 10 or 6sites | B (IC) |
| | | | X | | X | Implant strips of Samples | Rabbit | 4 strips/ animal | C |
| | | | X | | X | Implant Sample | Rat | 2 Samples/ animal | C |

a. Tests required for each class are indicate by "x" in appropriate columns.

b. Legend: A (IP)—Systemic Injection Test (Intraperitoneal); B—Intracutaneous Test (Intracutaneous); C—Implantation Test (Intramuscular or subcutaneous implantation)

2. Evaluation of Skin Reaction

| <u>Erythema and Eschar Formation</u> | <u>Score</u> |
|---|--------------|
| No erythema | 0 |
| Very slight erythema (barely perceptible) | 1 |
| Well-defined erythema | 2 |
| Moderate to severe erythema | 3 |
| Severe erythema (beet redness) to slight eschar formation (injuries in depth) | 4 |
| <u>Edema Formation *</u> | |
| No edema | 0 |
| Very slight edema (barely perceptible) | 1 |
| Slight edema (edges of area well-defined by definite raising) | 2 |
| Moderate edema (raised approximately 1 mm) | 3 |
| Severe edema (raised more than 1 mm and extending beyond area of exposure) | 4 |

*Excludes non-inflammatory (mechanical) edema from the blank or extract fluid



Test Plan Amendment

Detail of Amendment

Page 12: The test and control article are sterilized by dipping in 75% ethanol prior to implantation.

Reason of Amendment

The test article was already sterilized by EO, so dipping in 75% ethanol prior to implantation was not necessary.

This amendment does not affect the validity or interpretation of the data.

This amendment has been audited by the Quality Assurance Unit

Reference

1. Good Laboratory Practice for Nonclinical Laboratory Studies. Title 21 of the U.S. Code of Federal Regulations, Part 58. United States Food and Drug Administration.
2. Current OECD Principles of Good Laboratory Practice (Organization for Economic Cooperation and Development, Paris, ENV/MC/CHEM (98) 17).
3. United States Pharmacopeia 38. <88> Biological Reactivity Tests, *In Vivo*.
4. Biological evaluation of medical devices- Part 2: Animal welfare requirements. ISO 10993-2:2006.